<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Advances in medicine &#187; chronic diseases</title>
	<atom:link href="http://www.advances-in-medicine.com/category/chronic-diseases/feed" rel="self" type="application/rss+xml" />
	<link>http://www.advances-in-medicine.com</link>
	<description></description>
	<lastBuildDate>Fri, 16 Jul 2010 17:18:10 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>The Role of Inhaled Long-Acting Beta-2 Agonists in the Management of Asthma. LABAs as Adjunctive Therapy</title>
		<link>http://www.advances-in-medicine.com/2009/09/the-role-of-inhaled-long-acting-beta-2-agonists-in-the-management-of-asthma-labas-as-adjunctive-therapy.html</link>
		<comments>http://www.advances-in-medicine.com/2009/09/the-role-of-inhaled-long-acting-beta-2-agonists-in-the-management-of-asthma-labas-as-adjunctive-therapy.html#comments</comments>
		<pubDate>Wed, 02 Sep 2009 18:04:06 +0000</pubDate>
		<dc:creator>James</dc:creator>
				<category><![CDATA[chronic diseases]]></category>
		<category><![CDATA[Asthma]]></category>
		<category><![CDATA[lung]]></category>
		<category><![CDATA[polymorphisms]]></category>

		<guid isPermaLink="false">http://www.advances-in-medicine.com/?p=267</guid>
		<description><![CDATA[The various guidelines have defined the role of LABAs as adjunctive, given concurrently with an inhaled corticosteroid, and the combination is now considered preferred therapy for moderate and severe persistent asthma. This is supported by a large body of evidence that adding a LABA to the inhaled corticosteroid in patients poorly controlled on just the [...]]]></description>
		<wfw:commentRss>http://www.advances-in-medicine.com/2009/09/the-role-of-inhaled-long-acting-beta-2-agonists-in-the-management-of-asthma-labas-as-adjunctive-therapy.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Role of Inhaled Long-Acting Beta-2 Agonists in the Management of Asthma. Clinical Use of LABAs</title>
		<link>http://www.advances-in-medicine.com/2009/09/the-role-of-inhaled-long-acting-beta-2-agonists-in-the-management-of-asthma-clinical-use-of-labas.html</link>
		<comments>http://www.advances-in-medicine.com/2009/09/the-role-of-inhaled-long-acting-beta-2-agonists-in-the-management-of-asthma-clinical-use-of-labas.html#comments</comments>
		<pubDate>Wed, 02 Sep 2009 17:57:07 +0000</pubDate>
		<dc:creator>James</dc:creator>
				<category><![CDATA[chronic diseases]]></category>
		<category><![CDATA[Asthma]]></category>
		<category><![CDATA[lung]]></category>
		<category><![CDATA[polymorphisms]]></category>

		<guid isPermaLink="false">http://www.advances-in-medicine.com/?p=265</guid>
		<description><![CDATA[The LABAs are approved for chronic maintenance therapy of asthma, chronic obstructive pul¬monary disease and exercise-induced bronchospasm (EIB). Numerous trials have demonstrated the superiority of maintenance therapy with an inhaled LABA (administered twice daily) to maintenance therapy with an inhaled short-acting beta-2 agonist (administered four times daily). Therapy with LABAs improves lung function, bronchial hyperre-sponsiveness [...]]]></description>
		<wfw:commentRss>http://www.advances-in-medicine.com/2009/09/the-role-of-inhaled-long-acting-beta-2-agonists-in-the-management-of-asthma-clinical-use-of-labas.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Clinical Pharmacology of the LABAs</title>
		<link>http://www.advances-in-medicine.com/2009/09/clinical-pharmacology-of-the-labas.html</link>
		<comments>http://www.advances-in-medicine.com/2009/09/clinical-pharmacology-of-the-labas.html#comments</comments>
		<pubDate>Wed, 02 Sep 2009 17:52:59 +0000</pubDate>
		<dc:creator>James</dc:creator>
				<category><![CDATA[chronic diseases]]></category>
		<category><![CDATA[Asthma]]></category>
		<category><![CDATA[lung]]></category>
		<category><![CDATA[polymorphisms]]></category>

		<guid isPermaLink="false">http://www.advances-in-medicine.com/?p=263</guid>
		<description><![CDATA[LABAs differ from short-acting inhaled beta-2 agonists principally in having large side chains, increasing their lipophilicity. The greater water solubility of short-acting inhaled beta-2 agonists, such as albuterol, leads them to diffuse away from the beta-2-adrenergic receptors, limiting their duration of action. The greater lipophilicity of formoterol and salmeterol facilitates their partitioning and retention in [...]]]></description>
		<wfw:commentRss>http://www.advances-in-medicine.com/2009/09/clinical-pharmacology-of-the-labas.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Management of Asthma</title>
		<link>http://www.advances-in-medicine.com/2009/09/management-of-asthma.html</link>
		<comments>http://www.advances-in-medicine.com/2009/09/management-of-asthma.html#comments</comments>
		<pubDate>Wed, 02 Sep 2009 17:46:15 +0000</pubDate>
		<dc:creator>James</dc:creator>
				<category><![CDATA[chronic diseases]]></category>
		<category><![CDATA[Asthma]]></category>
		<category><![CDATA[lung]]></category>
		<category><![CDATA[polymorphisms]]></category>

		<guid isPermaLink="false">http://www.advances-in-medicine.com/?p=257</guid>
		<description><![CDATA[
National and international guidelines for the management of asthma concur on the goals of therapy (Table 1)  and on the components of the care necessary to achieve them (Table 2). The components of care involve eliminating or avoiding disease exacerbating factors, monitoring, education and pharmacotherapy. The guidelines agree that pharmacotherapy should consist of the treatment that [...]]]></description>
		<wfw:commentRss>http://www.advances-in-medicine.com/2009/09/management-of-asthma.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Role of Inhaled Long-Acting Beta-2 Agonists in the Management of Asthma</title>
		<link>http://www.advances-in-medicine.com/2009/09/the-role-of-inhaled-long-acting-beta-2-agonists-in-the-management-of-asthma.html</link>
		<comments>http://www.advances-in-medicine.com/2009/09/the-role-of-inhaled-long-acting-beta-2-agonists-in-the-management-of-asthma.html#comments</comments>
		<pubDate>Wed, 02 Sep 2009 14:56:07 +0000</pubDate>
		<dc:creator>James</dc:creator>
				<category><![CDATA[chronic diseases]]></category>
		<category><![CDATA[Asthma]]></category>
		<category><![CDATA[lung]]></category>
		<category><![CDATA[polymorphisms]]></category>

		<guid isPermaLink="false">http://www.advances-in-medicine.com/?p=251</guid>
		<description><![CDATA[The role of inhaled beta-2 agonists in the management of asthma has changed significantly over the last several years. This review outlines the most recent understanding of the pathophysiology of asthma and the studies that define the roles lhat both short- and long-acting beta-2 agonists play in therapy for this disease. A concentration on the [...]]]></description>
		<wfw:commentRss>http://www.advances-in-medicine.com/2009/09/the-role-of-inhaled-long-acting-beta-2-agonists-in-the-management-of-asthma.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>CHRONIC FATIGUE SYNDROME &#8211; Pharmacologic Therapy</title>
		<link>http://www.advances-in-medicine.com/2008/04/chronic-fatigue-syndrome-pharmacologic-therapy.html</link>
		<comments>http://www.advances-in-medicine.com/2008/04/chronic-fatigue-syndrome-pharmacologic-therapy.html#comments</comments>
		<pubDate>Wed, 23 Apr 2008 08:26:35 +0000</pubDate>
		<dc:creator>Alex</dc:creator>
				<category><![CDATA[chronic diseases]]></category>

		<guid isPermaLink="false">http://www.advances-in-medicine.com/2008/04/chronic-fatigue-syndrome-pharmacologic-therapy.html</guid>
		<description><![CDATA[No treatment has been proved to benefit patients with CFS in large randomized controlled trials that have been replicated by other investigators in other populations of patients. Moreover, without a better understanding of the pathogenesis of CFS, it is unlikely that definitive treatment will be identified. Indeed, the pharmacologic treatment of CFS primarily involves the [...]]]></description>
		<wfw:commentRss>http://www.advances-in-medicine.com/2008/04/chronic-fatigue-syndrome-pharmacologic-therapy.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>MANAGEMENT OF CHRONIC FATIGUE SYNDROME</title>
		<link>http://www.advances-in-medicine.com/2008/04/management-of-chronic-fatigue-syndrome.html</link>
		<comments>http://www.advances-in-medicine.com/2008/04/management-of-chronic-fatigue-syndrome.html#comments</comments>
		<pubDate>Tue, 22 Apr 2008 19:44:40 +0000</pubDate>
		<dc:creator>Alex</dc:creator>
				<category><![CDATA[chronic diseases]]></category>

		<guid isPermaLink="false">http://www.advances-in-medicine.com/2008/04/management-of-chronic-fatigue-syndrome.html</guid>
		<description><![CDATA[Nonpharmacologic Management
Management of the patient with CFS requires more than pharmacotherapy. First, the clinician must make a personal judgment as to whether patients are accurately relating their symptoms -both those that they admit to and those that they deny. CFS is an illness defined only by symptoms. Thus, an occasional patient seeking secondary gain may [...]]]></description>
		<wfw:commentRss>http://www.advances-in-medicine.com/2008/04/management-of-chronic-fatigue-syndrome.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
